Interleukin66307Interleukin6

4 Hydroxynonenal

ADH AVP Vasopressin

Antiinflammatory compounds

Arthritis (rheumatoid)

Bone (Metastasis)

Cardiovascular risk

CD31 PECAM1

Edaravone

ERS UFR (Diseases)

Fatty acids (Omega3)

Fibrosis

GADD153 CHOP

IgA nephropathy

Inflammation (BASKET)

iNOS

Interferon gamma

Interleukin10

Interleukin24 MDA7

Interleukin6

Ischemia reperfusion

Keloid

Lipid electrophiles

Neoplasia (Invasion and metastasis)

Neoplasia (Oncolytic virus)

NFKB

RAAS (AngiotensinII)

Receptor (Interleukin6 GP130)

Sodium (Hyponatriemia)

SXBP1

Systemic lupus erythematosus

TNF alpha

Tocilizumab ttIL6

2008
1
Roles of IL-6-gp130 Signaling in Vascular Inflammation.
[19936194] Curr Cardiol Rev 4(3):179-92 (2008)
2005
2
Directing transition from innate to acquired immunity: defining a role for IL-6.
[16148087] J Immunol 175(6):3463-8 (2005)
2006
3
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
[16707558] J Leukoc Biol 80(2):227-36 (2006)
2006
4
Interleukin-6 trans-signalling in chronic inflammation and cancer.
[16640655] Scand J Immunol 63(5):321-9 (2006)
2003
5
Interleukin-6 biology is coordinated by membrane bound and soluble receptors.
[14515143] Acta Biochim Pol 50(3):603-11 (2003)
1996
6
Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation?
[8916880] Ann Surg 224(5):647-64 (1996)
2007
7
Decomposition of diverse litter mixtures in streams.
[17489470] Ecology 88(1):219-27 (2007)
2003
8
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
[14581334] Clin Cancer Res 9(13):4653-65 (2003)
1989
9
The biology of interleukin-6.
[2473791] Blood 74(1):1-10 (1989)
2010
10
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.
[19854855] Rheumatology (Oxford) 49(1):15-24 (2010)
2006
11
Interleukin-6 and rheumatic diseases.
[16899108] Arthritis Res Ther 8 Suppl 2(-):S4 (2006)
2010
12
The soluble interleukin 6 receptor takes its place in the pantheon of interleukin 6 signaling proteins: phenoconversion of cardiac fibroblasts to myofibroblasts.
[20606105] Hypertension 56(2):193-5 (2010)
2010
13
The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation.
[20202975] Cardiovasc Res 86(2):211-8 (2010)
2011
14
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
[21881215] J Clin Invest 121(9):3375-83 (2011)
2008
15
Muscle as an endocrine organ: focus on muscle-derived interleukin-6.
[18923185] Physiol Rev 88(4):1379-406 (2008)
2002
16
Muscle-derived interleukin-6: mechanisms for activation and possible biological roles.
[12205025] FASEB J 16(11):1335-47 (2002)
2007
17
Interleukin-6 and its receptor in cancer: implications for translational therapeutics.
[17849470] Cancer 110(9):1911-28 (2007)
2003
18
Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
[12773095] Biochem J 374(Pt 1):1-20 (2003)
2011
19
Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy.
[21345134] Future Oncol 7(2):161-4 (2011)
2010
20
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir.
[20689230] Proc Jpn Acad Ser B Phys Biol Sci 86(7):717-30 (2010)
2005
21
IL-6 and extracellular matrix remodeling.
[16266225] Rev Esp Enferm Dig 97(8):575-95 (2005)
2002
22
The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24.
[12055212] J Immunol 168(12):6041-6 (2002)
2005
23
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
[15585417] Mol Ther 11(1):160-72 (2005)
2011
24
C/EBP homologous protein deficiency attenuates myocardial reperfusion injury by inhibiting myocardial apoptosis and inflammation.
[21330607] Arterioscler Thromb Vasc Biol 31(5):1124-32 (2011)
2011
25
Structure-activity analysis of diffusible lipid electrophiles associated with phospholipid peroxidation: 4-hydroxynonenal and 4-oxononenal analogues.
[21291287] Chem Res Toxicol 24(3):357-70 (2011)
2010
26
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
[21116333] Drug Des Devel Ther 4(-):263-78 (2010)
2011
27
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.
[21625400] Cancer Manag Res 3(-):177-89 (2011)
2010
28
Interleukin-6 in bone metastasis and cancer progression.
[20335016] Eur J Cancer 46(7):1223-31 (2010)
2004
29
Rationale for interleukin-6 blockade in systemic lupus erythematosus.
[15230289] Lupus 13(5):339-43 (2004)
2011
30
Hyponatremia and inflammation: the emerging role of interleukin-6 in osmoregulation.
[21196778] Nephron Physiol 118(2):45-51 (2011)
2004
31
Interleukin-6 and cardiovascular diseases.
[15090695] Jpn Heart J 45(2):183-93 (2004)
2007
32
Essential role of IL-6 signaling pathway in keloid pathogenesis.
[17384473] J Nihon Med Sch 74(1):11-22 (2007)
2010
33
n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis.
[20189790] Prostaglandins Leukot Essent Fatty Acids 82(4-6):251-8 (2010)


Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.